Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive
disease to review and possibly improve therapeutic treatment options. Surgery, radiation …

Background Recently, a variety of clinical trials have shown that apatinib, a small-molecule
anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including …

Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …

Apatinib [Aitan®(brand name in China)], also known as rivoceranib, is a novel, small
molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase …

Introduction Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …

Metastasis is one of the main issues in cancer treatment and it has been documented that
angiogenesis plays an important role in this process. Studies showed that vascular …

Apatinib, a novel tyrosine kinase inhibitor (TKI), has been confirmed for its efficacy and
safety in the treatment of advanced gastric carcinoma and some other solid tumors …

Tumour microenvironment (TME) is a key determinant of tumour growth and metastasis.
TME could be very different for each type and location of tumour and TME may change …

Purpose Non-small cell lung cancer (NSCLC) accounts for about 85% in all cases of lung
cancer. In recent years, molecular targeting drugs for NSCLC have been developed rapidly …